| Title |
The Economic Costs of Type 2 Diabetes: A Global Systematic Review
|
|---|---|
| Published in |
PharmacoEconomics, March 2015
|
| DOI | 10.1007/s40273-015-0268-9 |
| Pubmed ID | |
| Authors |
Till Seuring, Olga Archangelidi, Marc Suhrcke |
| Abstract |
There has been a widely documented and recognized increase in diabetes prevalence, not only in high-income countries (HICs) but also in low- and middle-income countries (LMICs), over recent decades. The economic burden associated with diabetes, especially in LMICs, is less clear. |
X Demographics
The data shown below were collected from the profiles of 32 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 13 | 41% |
| United States | 2 | 6% |
| Germany | 2 | 6% |
| New Zealand | 1 | 3% |
| Canada | 1 | 3% |
| Saudi Arabia | 1 | 3% |
| Spain | 1 | 3% |
| Luxembourg | 1 | 3% |
| Thailand | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 8 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 16 | 50% |
| Practitioners (doctors, other healthcare professionals) | 7 | 22% |
| Scientists | 7 | 22% |
| Science communicators (journalists, bloggers, editors) | 2 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 1,189 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | <1% |
| United Kingdom | 2 | <1% |
| Germany | 1 | <1% |
| Indonesia | 1 | <1% |
| Brazil | 1 | <1% |
| Israel | 1 | <1% |
| Switzerland | 1 | <1% |
| Malaysia | 1 | <1% |
| India | 1 | <1% |
| Other | 2 | <1% |
| Unknown | 1176 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 241 | 20% |
| Student > Bachelor | 143 | 12% |
| Student > Ph. D. Student | 135 | 11% |
| Researcher | 122 | 10% |
| Student > Postgraduate | 69 | 6% |
| Other | 182 | 15% |
| Unknown | 297 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 313 | 26% |
| Nursing and Health Professions | 125 | 11% |
| Biochemistry, Genetics and Molecular Biology | 64 | 5% |
| Agricultural and Biological Sciences | 62 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 52 | 4% |
| Other | 226 | 19% |
| Unknown | 347 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 87. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 February 2020.
All research outputs
#494,909
of 25,837,817 outputs
Outputs from PharmacoEconomics
#10
of 2,004 outputs
Outputs of similar age
#5,777
of 280,072 outputs
Outputs of similar age from PharmacoEconomics
#1
of 22 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,004 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,072 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.